A multi-center, open label phase I/II study of CEP-701 (lestaurtinib) in adults with myelofibrosis
ID Number 07-0548-00104Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to find the safest dose of CEP-701. Treatment for myelofibrosis is unsatisfactory and there is no medication specifically used in the treatment of myelofibrosis. There is a protein found to be present in the majority of myelofibrosis patients (JAK2) and the investigational drug CEP-801 is being studied to see if it will stop this protein from functioning and thereby controll the disease.
Recruiting Patients: Yes